Fc Receptor-ACE2 Conjugates and Use Thereof

Abstract

Provided herein are, inter alia, peptides capable of binding viral proteins and thereby preventing viral infection, replication and spread (e.g., SARS CoV-2). The conjugates provided herein include an dimerizing domain (e.g., Fc domain) attached through a peptide linker to a protein domain (viral protein binding domain). The viral protein binding domain is capable of binding a viral protein, for example, a viral envelope protein or a portion thereof.

1 . A peptide comprising a dimerizing domain bound to a viral protein binding domain through a chemical linker, wherein said viral protein binding domain is bound to the C-terminus of said dimerizing domain. 
     
     
         2 . The peptide of  claim 1 , wherein said viral protein binding domain is a Severe Acute Respiratory Syndrome (SARS)-coronavirus (CoV) protein binding domain or a Middle East Respiratory Syndrome (MERS)-coronavirus (CoV) protein binding domain. 
     
     
         3 . (canceled) 
     
     
         4 . The peptide of  claim 1 , wherein said viral protein binding domain is a spike protein binding domain. 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . The peptide of  claim 1 , wherein said viral protein binding domain is an angiotensin converting enzyme 2 (ACE2) domain. 
     
     
         8 . The peptide of  claim 1 , wherein said viral protein binding domain comprises the sequence of SEQ ID NO:1, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8. 
     
     
         9 . The peptide of  claim 1 , wherein said dimerizing domain is a Fc dimerizing domain. 
     
     
         10 . The peptide of  claim 1 , wherein said dimerizing domain comprises a CH2 and a CH3 domain. 
     
     
         11 .- 15 . (canceled) 
     
     
         16 . The peptide of  claim 1 , wherein said chemical linker is a peptide linker. 
     
     
         17 . (canceled) 
     
     
         18 . The peptide of  claim 16 , wherein said peptide linker has a length of less than 20 amino acid residues. 
     
     
         19 .- 25 . (canceled) 
     
     
         26 . The peptide of  claim 1 , wherein said peptide is a first peptide and said dimerizing domain is a first dimerizing domain. 
     
     
         27 . The peptide of  claim 26 , wherein said first dimerizing domain is bound to a second peptide comprising:
 a second dimerizing domain bound to a second viral protein binding domain through a second chemical linker, wherein said first viral protein binding domain is bound to the C-terminus of said second dimerizing domain; and   wherein said first dimerizing domain and said second dimerizing domain are covalently bound together thereby binding said first peptide to said second peptide.   
     
     
         28 . The peptide of  claim 27 , wherein said second viral protein binding domain is a Severe Acute Respiratory Syndrome (SARS)-coronavirus (CoV) protein binding domain or a Middle East Respiratory Syndrome (MERS)-coronavirus (CoV) protein binding domain. 
     
     
         29 . (canceled) 
     
     
         30 . The peptide of  claim 27 , wherein said second viral protein binding domain is a spike protein binding domain. 
     
     
         31 .- 34 . (canceled) 
     
     
         35 . The peptide of  claim 27 , wherein said second dimerizing domain is an Fe dimerizing domain. 
     
     
         36 .- 53 . (canceled) 
     
     
         54 . A peptide complex comprising:
 (i) a first peptide comprising a first dimerizing domain bound to a first viral protein binding domain through a first chemical linker, wherein said first viral protein binding domain is bound to the C-terminus of said first dimerizing domain; and   (ii) a second peptide comprising a second dimerizing domain bound to a second viral protein binding domain through a second chemical linker, wherein said second viral protein binding domain is bound to the C-terminus of said second dimerizing domain;   wherein said first dimerizing domain and said second dimerizing domain are bound together thereby binding said first peptide to said second peptide.   
     
     
         55 . An isolated nucleic acid encoding a peptide of  claim 1 . 
     
     
         56 . An expression vector comprising the nucleic acid of  claim 55 . 
     
     
         57 . (canceled) 
     
     
         58 . A method of treating a viral disease in a subject in need thereof, said method comprising administering to a subject a therapeutically effective amount of a peptide of  claim 1 , thereby treating an infectious disease in said subject. 
     
     
         59 . The method of  claim 58 , wherein said viral disease is SARS. 
     
     
         60 . (canceled) 
     
     
         61 . A pharmaceutical composition comprising a therapeutically effective amount of a peptide of  claim 1  and a pharmaceutically acceptable excipient.